Citadel Advisors’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-470
Closed -$2.38K 13134
2025
Q4
$2.38K Buy
+470
New +$5.12K ﹤0.01% 12477
2025
Q2
Sell
-863
Closed -$8.02K 12846
2025
Q1
$8.02K Sell
863
-1,177
-58% -$22.5K ﹤0.01% 13663
2024
Q4
$45.9K Buy
2,040
+1,817
+815% +$57.4K ﹤0.01% 12477
2024
Q3
$8.38K Buy
223
+90
+68% +$3.46K ﹤0.01% 13305
2024
Q2
$5K Buy
133
+26
+24% +$946 ﹤0.01% 13441
2024
Q1
$3.58K Sell
107
-386
-78% -$14K ﹤0.01% 13883
2023
Q4
$19.7K Sell
493
-377
-43% -$13.3K ﹤0.01% 12633
2023
Q3
$27.7K Buy
870
+43
+5% +$1.62K ﹤0.01% 12355
2023
Q2
$27.5K Buy
827
+37
+5% +$1.42K ﹤0.01% 12442
2023
Q1
$35.1K Buy
790
+377
+91% +$30.2K ﹤0.01% 12584
2022
Q4
$31.2K Sell
413
-80
-16% -$7.49K ﹤0.01% 12693
2022
Q3
$48K Sell
493
-234
-32% -$32.7K ﹤0.01% 11659
2022
Q2
$122K Sell
727
-963
-57% -$146K ﹤0.01% 11190
2022
Q1
$313K Sell
1,690
-1,520
-47% -$315K ﹤0.01% 10503
2021
Q4
$860K Buy
3,210
+33
+1% +$8.66K ﹤0.01% 8327
2021
Q3
$927K Sell
3,177
-2,126
-40% -$620K ﹤0.01% 8343
2021
Q2
$1.31M Sell
5,303
-94
-2% -$24.2K ﹤0.01% 7639
2021
Q1
$1.54M Sell
5,397
-2,890
-35% -$1.15M ﹤0.01% 7026
2020
Q4
$2.31M Buy
8,287
+5,347
+182% +$1.98M ﹤0.01% 5059
2020
Q3
$1.2M Sell
2,940
-1,017
-26% -$522K ﹤0.01% 5701
2020
Q2
$2.3M Sell
3,957
-1,380
-26% -$630K ﹤0.01% 4327
2020
Q1
$1.22M Buy
+5,337
New +$925K ﹤0.01% 4968

Other funds holding CODX

Citadel Advisors's CODX Position: Q4 2025 in Review

Citadel Advisors sold out of Co-Diagnostics (CODX) in Q4 2025, closing a stake of 353 shares — an estimated $3.84K sold.

Citadel Advisors first reported a position in CODX in Q1 2018 and held it in 25 quarters. The position peaked at $5.4M in Q2 2020. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.

  • Citadel Advisors reported no remaining Co-Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 353 Co-Diagnostics shares in Q4 2025, an estimated $3.84K.
  • Citadel Advisors first reported a position in Co-Diagnostics in Q1 2018 and held it in 25 quarters.
  • Citadel Advisors's Co-Diagnostics position peaked at $5.4M in Q2 2020.
  • 30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.